We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sugar Molecules, Not Antibodies, Used to Detect Influenza Viruses

By Biotechdaily staff writers
Posted on 14 Jul 2008
A fast, sensitive test uses sugar molecules rather than antibodies to detect influenza viruses. More...


Influenza is a contagious disease, which causes over 150 million infections per year in the United States alone. A new study has demonstrated glycoconjugate-based viral capture and a potential path for the discriminatory detection of intact influenza viruses in the presence of the innate enzymatic activity of viral nucleic acids (NAs).

The capture of intact influenza viruses is of potential benefit for clinical diagnostics.
Conventional tests for influenza viruses, including avian flu, rely on antibodies to recognize viruses. However, antibody-based tests can be expensive and require refrigeration to remain stable. The test using sugar molecules requires no refrigeration and it can be used in remote areas of the world where new influenza viruses frequently emerge.

In a new study, Jurgen Schmidt, Ph.D., from the Los Alamos National Laboratory (NM, USA), Suri Iyer, Ph.D., assistant professor in the department of chemistry, University of Cincinnati, (OH, USA), and colleagues developed artificial forms of sialic acid, a sugar molecule found on the surface of cells that flu viruses attach to when they attack humans.

The scientists synthesized robust, biotinylated biantennary sialylglycoconjugates and demonstrated their ability to differentiate between two types of influenza A strains. In laboratory tests, they showed that the highly selective artificial sugars could be used to quickly capture and recognize two common strains of influenza viruses, H1N1, which infects birds, and H3N2, which infects pigs and humans. They used the molecules to differentiate between two strains (Sydney and Beijing) commonly found in human infections without isolating the viral RNA or surface glycoproteins. The sugars remain stable for several months, can be produced in large quantities, and exhibit extended shelf- life.

The new method appeared in the July 2, 2008 issue of the Journal of the American Chemical Society, a weekly publication.


Related Links:
Los Alamos National Laboratory
University of Cincinnati

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
All-in-One Molecular System
AIO M160
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.